Clinical Trial

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumours or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumour and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa clinical trial
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-06-29; most recent amendment 2025-10-02.
Status change: Not Yet Recruiting → Recruiting 2023-04-27
Trial Details
NCT Number NCT04954599
Lead Sponsor Maastricht University Medical Center
Collaborators: Erasmus Medical Center, Jules Bordet Institute, Academisch Ziekenhuis Maastricht, Vall d'Hebron Institute of Oncology, University Ghent
Conditions Unspecified Adult Solid Tumor, Protocol Specific
Enrollment 126 participants
Start Date 2023-05-30
Primary Completion 2027-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-10-07